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Abstract:  Graves’ disease (GD) is the most common cause of thyrotoxicosis and often involves the orbits. Graves’ 
ophthalmopathy (GO), also known as Thyroid Eye Disease (TED), can be clinically significant and advance to sight-
threatening stages. Our knowledge of the immunogenetic pathophysiology of GO is rapidly expanding. The present 
review is an attempt to summarize the current state of knowledge on the immunogenetics of GO. First we briefly review 
the epidemiology and clinical importance of GO, and then we describe in detail the macromolecular pathogenesis and 
finally immunogenetics of GO. Discrepancies between the results from various reports and the limitations of the available 
data are discussed. In particular, there is a scarcity of data from non-Asian populations. While several studies have 
demonstrated significant associations between polymorphisms in certain genes (especially CTLA-4, HLA-DRB-1, and 
TNF- ), there is a need for studies that investigate the relationship between polymorphisms and both serum and local 
concentrations of the resulting proteins. A complete understanding of GO susceptibility and pathogenesis has not been yet 
possible due to a number of important knowledge gaps that need to be filled by future research.  
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1. INTRODUCTION: GRAVES’ DISEASE 
  Graves’ disease (GD), the single most common cause of 
thyrotoxicosis, is an autoimmune disease of aberrant 
antibody production [1]. Antibodies directed against 
thyrotropin receptor (TSHR) target the endothelial surface of 
thyroid follicular cells where these receptors are most 
abundant [2]. Although almost any organ may be involved in 
GD, GD is classically described as a syndrome consisting of 
hyperthyroidism, goiter, orbitopathy, and dermopathy. 
Follicular hyperplasia, intracellular colloid droplets, cell 
scalloping, a reduction in follicular colloid, and a patchy T-
cell-predominant lymphocytic infiltration characterize the 
histology of the thyroid gland in GD. GD is primarily a T 
helper-2 (Th2) autoimmune disease since antibody secretion 
against TSHR is the cornerstone of the disease 
pathophysiology [3].  
  Several risk factors have been identified for GD. Genetic 
susceptibility is an important concept. The disease tends to 
run in families (concordance rate of 20%-40% in 
monozygotic twins and greater than 10% in siblings) and has 
a predilection to women (female to male ratio of 7:1) [4-
5].  Infections of the thyroid gland have been proposed to 
trigger the autoimmune cascade leading to GD, but the 
available evidence is slim [6]. Many patients with GD report 
a history of some type of psychological stress before the   
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onset of the disease. Rebound immunologic hyperactivity 
following stress-related, corticosteroid-induced immune 
suppression has been proposed as a mechanism for the role 
of stress in GD [7-9]. Estrogen-induced immunologic 
reactivity has been linked to GD, consistent with the 
observation that GD affects women much more commonly 
than men. Interestingly, however, susceptibility to GD 
continues after menopause, suggesting that the X-
chromosome rather than estrogen might be the source of 
enhanced susceptibility [10]. Smoking is another risk factor 
for GD, with largely unknown mechanisms [11-12].  
  The onset of GD in up to 30% of women is within a year 
after pregnancy [13]. Although the mechanisms for this 
interesting association are not clear, the presence of fetal 
cells in maternal tissues after pregnancy (fetal 
microchimerism) might play a role [14]. Finally, iodine and 
iodine-containing drugs such as amiodarone may predispose 
a susceptible individual to GD [15]. It has been suggested 
that iodine (and amiodarone) damages thyrocytes and makes 
thyroid antigens exposed to the immune system [16]. In the 
iodine-deficient susceptible patient, iodine can precipitate 
GD by allowing TSHR antibodies to more effectively 
stimulate thyroid hormone formation.  
  The literature on GD is extensive. The focus of our 
attention in this article is on a specific complication of GD, 
namely Graves’ ophthalmopathy (GO) or Thyroid Eye 
Disease (TED). First we briefly review the epidemiology and 
clinical importance of GO, and then we will describe in 
detail the macromolecular pathogenesis and finally 
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2. GRAVES’ OPHTHALMOPATHY: EPIDEMIO-
LOGY AND CLINICAL IMPORTANCE 
  The GD process is not limited to the thyroid gland. In a 
subset of patients GD also involves the pretibial skin and the 
orbit, the latter known as GO or TED [17]. Orbital 
involvement is not merely a byproduct of hyperthyroidism; 
rather, the same underlying immune processes involving 
TSHR antibodies are active in the orbits [17]. TSHR 
antibody titers seem to be positively correlated with clinical 
features of GO, whereas thyroid stimulating immunoglobulin 
(TSI) and thyroid peroxidase (TPO) antibody do not [18]. 
  The degree of eye involvement among GD patients varies 
considerably from very mild cases with tenuous changes 
only detected on imaging, to more severe sight-threatening 
forms with optic nerve compression [17]. Clinically evident 
GO can be detected in 25-50% of patients sometime in the 
course of disease but only 3-5% experience debilitating 
forms [1]. In the presence of lid retraction, lid lag, proptosis, 
extraocular muscle involvement, or optic nerve dysfunction, 
a clinical diagnosis of GO can be made [19]. In a 
retrospective cohort of 120 subjects with GO, the most 
common presentation was lid retraction (90%), followed by 
proptosis (62%) [20]. These manifestations are due to 
mechanical compression of the orbit stemming from 
expansive changes in orbital connective tissues and 
extraocular muscles. With increased orbital pressure, 
lymphatic and venous return is hindered and congestive 
swelling develops [21]. Patients often complain of redness, 
swelling, grittiness, foreign body sensation, dryness, 
excessive tearing, restricted eye movements, diplopia, and 
inability to close the eyes during sleep [17]. Of the 
extraocular muscles involved, inferior rectus is the most 
commonly affected muscle followed by medial rectus, 
superior rectus, and lateral rectus, respectively [22]. 
  A number of scoring systems has been developed to 
define the severity of GO, among which the NOSPECS and 
Clinical Activity Score (CAS) systems have been widely 
used in research and practice. The NOSPECS system (1977) 
uses a 7 class scheme from 0 (no signs or symptoms) to 6 
(sight loss) [23]. Classes 2 through 6 are further divided by 
grades a, b, or c; for example in class 5 (corneal 
involvement), grades a, b, and c correspond to “stippling of 
cornea”, “ulceration”, and “clouding, necrosis, perforation”, 
respectively [23]. The CAS system (1989), on the other 
hand, adopts a ten-item questionnaire with the sum of all 
positive scores being indicative of disease severity [24]. The 
10 items of CAS concern the following four signs of 
inflammation: pain (2 items), redness (2 items), swelling (4 
items), and impaired function (1 item for movement 
restriction, and 1 item for impaired visual acuity) [24-25].  
  Similar to other autoimmune conditions, GO has a 
multifactorial etiology; genetic and environmental factors 
interact in concert and trigger a deviant process that presents 
self-antigens as non-self [26]. Risk factors for GO 
development or progression include ethnicity (African-
American > European > Asian), sex, treatment with 
radioactive iodine, and hyper- or hypothyroidism [27]. 
Certain anatomical features of the orbital walls (i.e. wide 
angle of the lateral wall) have also been linked to more 
severe forms since orbits with these features cannot provide 
adequate space for orbital expansion [27]. Among 
modifiable risk factors, smoking has been repeatedly linked 
to both development and progression of GO with odds ratios 
ranging from 7.7 to 20.2 [11, 28]. Smoking cessation has 
been consistently advised at primary, secondary, and tertiary 
levels of prevention [29]. Like other diseases of autoimmune 
origin, women are more likely to develop GO [1, 27]. An 
annual age-adjusted incidence of 2.9 per 100,000 in men and 
16 per 100,000 in women has been reported for GO [30]. 
Compared with men, the peak incidence of GO is about five 
years earlier in women than in men [30]. With further 
follow-up of a cohort of patients with GO in Olmsted for 9.8 
years, GO regressed in most cases, however at least one third 
of patients were discontented about the appearance of their 
orbit [31]. Serious complications including permanent sight 
loss (2.2%), and permanent diplopia (2.2%) were also noted, 
albeit rarely [31]. Although women are more affected, men 
are more likely to develop severe GO [27, 32]. In a cohort of 
2,045 subjects with GD, the rate of GO with NOSPECS 
classes 4-6 (severe disease), was 30.4% and 21.3% in men 
and women, respectively [32]. Finally, radioactive iodine 
treatment of hyperthyroidism has been linked to the 
progression and worsening of GO. Radioiodine therapy 
seems to induce substantial increases in the serum 
concentrations of TSHR antibodies, which might trigger or 
exacerbate GO [33]. Risk factors that increase the likelihood 
of this complication include smoking, moderate to severe 
GO [34], and a high baseline serum concentration of 
triiodothyronine [35]. 
3. GRAVES’ OPHTHALMOPATHY: MACROMOLE-
CULAR PATHOGENESIS 
  The TSHR-major histocompatibility complex class II 
(TSHR-MHC II) complex is internalized and processed by 
antigen-presenting cells (APC) and presented primarily to 
CD4+ T-cells via the T-cell receptor (TCR). Activated T-
cells recruit B-cells through CD40-CD154 ligation. B-cells 
differentiate into plasma cells via interferon  (INF- ) and 
interleukin 2 (IL-2), activated T-cells recognize THSR on the 
orbital fibroblasts, and hence a site-specific immune 
response is initiated [17]. Little is known about the details of 
the events leading to the formation of TSHR-MHC II 
anomalous connection, nonetheless a number of mechanisms 
have been proposed. Infections can (i) cause an imbalance in 
cytokine production, (ii) induce non-specific activation of T- 
and B-cells through superantigens and mitogens, and (iii)
alter self-antigens to a degree that are perceived as non-self 
[1]. Some studies have found a link between a history of 
infestation with Yersinia species and GD [6, 36]. Yersinia 
entrocolitica displays membrane proteins similar to TSHR (a 
requirement for the process of molecular mimicry) and can 
bind to TSH, [37]. 
  A compelling body of evidence points toward a central 
role for orbital fibroblasts in the pathogenesis of GO [1]. 
Higher levels of TSH mRNA have been observed in GO 
fibroblasts compared with their normal counterparts [38]. 
They also express higher levels of insulin-like growth factor-
1 receptor (IGF-1R) that may be recognized as an 
autoantigen and contribute to GO pathogenesis [39] (see 
below). There are two subpopulations of fibroblasts with 
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The Thy-1+ (CD90) subpopulation produces high levels of 
hyaluronan, whereas the Thy-1- cells are capable of 
differentiating into adipose tissue [40]. Hyaluronan, a 
hydrophilic glycosaminoglycan, absorbs high quantities of 
water and contributes to the expansive remodeling in the 
orbital space and within muscle fibers [41]. Hyaluronan 
production is enhanced with IL-2 and transforming growth 
factor   (TGF- ) secretion [42]. The process of adipogenesis, 
on the other hand, is mediated through activation of 
peroxisome proliferator-activated receptor gamma (PPAR-  )
[43]. PPAR-   not only drives adipogenesis, but has 
immunomodulatory roles as well. When activated, PPAR-  
abates chemokines CXCL9, 10, 11, and INF-   that are 
characteristic of T helper-1 type (Th1) response, hence 
contributing to the transition from Th1- to Th2-mediated 
immunity [44]. While IL-6 enhances adipogenesis [45], 
tumor necrosis factor   (TNF- ), TGF- , and INF-   inhibit 
the process [46]. Mature adipocytes augment the expression 
of TSHR, and significantly contribute to the maintenance of 
the disease process [47]. 
  Recruitment and infiltration of assorted classes of 
immune cells in the orbit is dependent upon an abundant 
pool of the produced cytokines. Cytokines have important 
putative roles in GO development, progression, and 
regression and are produced by activated T-cells (mostly 
CD4+ cells), macrophages, B-cells, and orbital fibroblasts 
[48-50]. Th1 lymphocytes and their associated family of 
cytokines [TNF- , interleukin 1  (IL-1 ), INF-  , IL-2, and 
interleukin 12 (IL-12)] [51] predominate the orbit early in 
the course of the disease and promote the active phase of 
GO. Later in the course of the disease, the Th2 family [with 
interleukin 4 (IL-4), interleukin 5 (IL-5), and interleukin 10 
(IL-10)] [52] takes over, a transition associated with 
maintenance and resolution of the disease [53-54]. The 
orbital fibroblasts directly interact with activated T-cells 
through CD40-CD154 ligation. Indeed, the orbital fibroblast 
of patients with GO show higher levels of expression of 
CD40 than their normal counterparts [55]. CD40 belongs to 
the TNF-R family of receptors and engages in B-cell 
regulation, proliferation, antibody production, and 
conversion to memory cells [26]. With ligation of surface 
CD40 with CD154, the incited fibroblasts produce 
interleukin 6 (IL-6), interleukin 8 (IL-8), and macrophage 
chemoattractant protein-1 (MCP-1) [55]. 
  As mentioned above, TSHR is the dominant autoantigen 
responsible for the brisk immune activation in GO. However, 
there seem to be other self-antigens involved in the disease 
process. When IGF-1R (expressed on the surface of 
fibroblasts) is activated by antibodies extracted from sera of 
GD patients, T-cell chemo-attractants are upregulated [56]. 
Interestingly, TSHR and IGF-1R co-localize on the outer and 
inner membranes of both thyrocytes and orbital fibroblasts, 
raising the possibility of functional interactions between the 
two receptors [57]. Antibodies directed against extraocular 
muscle proteins (namely G2s and Fp) [58] have also been 
linked to GO. There have been arguments, however, that in 
the presence of an intact cell structure, a humoral response 
against intracellular proteins such as G2s and Fp is unlikely. 
A plausible explanation is that these proteins are released in 
the serum from damaged cells late in the disease process and 
are more indicative of disease severity than its causal 
underpinnings [21, 58].  
  What makes the connective tissue of the eyes particularly 
susceptible to GD? Recent studies have shed light on this 
puzzling question. Orbital fibroblasts manifest increased 
production of prostaglandin E2 when exposed to IL-1  or 
leukoregulin in-vitro [48]. These fibroblasts exhibit a more 
vigorous inflammatory response than those from the skin or 
lungs when stimulated by platelet-derived growth factor-BB 
[44]. Collectively, orbital fibroblasts are unique in the sense 
that they not only manifest an intense inflammatory 
response, but are also actively involved in the process by 
secreting various cytokines and chemoattractants [39]. 
4. GRAVES’ OPHTHALMOPATHY: IMMUNOGEN-
ETICS  
  In this section, we provide a detailed review of the 
immunogenetic associates of GO. Genetic factors related to 
cytokines, human leucocyte antigens (HLA), cytotoxic T-
lymphocyte antigen 4 (CTLA-4), and other loci [Toll-like 
receptors (TLR), B7 molecules, etc] are discussed in separate 
sections. A summary of the relevant studies is provided in 
Table 1. Fig. (1) provides a schematic summary of the most 
important immunogenetic mechanisms in GO susceptibility 
and progression.  
4.1. Cytokines 
  Considering that GO is an autoimmune condition, any 
imbalance between the production of pro- and anti-
inflammatory cytokines can alter the downstream cascade of 
reactions and trigger the autoimmune response [59-60]. 
Therefore, single-nucleotide polymorphisms in the cytokine 
genes which influence the expression of the pro- and anti-
inflammatory cytokines can protect from or promote the 
development of GO [59]. In an exhaustive immunogenetic 
series of studies in Iran, we have explored the association 
between cytokine gene polymorphisms and GO [61-63]. We 
identified significant associations between a number of 
polymorphisms in pro- and anti-inflammatory cytokine 
genes and GO (Table 1).  
  Cytokines released predominantly by leukocytes 
infiltrating the retro-orbital tissues are likely to play a key 
role in the cascade of the autoimmune reactions in the orbit 
[64]. Although several significant associations between 
genetic polymorphisms in cytokine genes and GO have been 
described, the immediate consequences of cytokine gene 
polymorphisms are not well studied. Such consequences 
include changes in serum and local concentrations of the 
cytokines as well their activity levels. The available literature 
on this subject is scarce, and a comprehensive study would 
be of great value. Overall, there are many contradictory 
results regarding the association between polymorphisms of 
cytokine genes and GO, likely reflecting different genetic 
patterns of susceptibility among different ethnic groups [65-
66]. 
  Among several cytokines studied, the role of 
polymorphisms in the cytokines of the IL-1 family and TNF-
  in genetic susceptibility to GO seems to be the strongest. 
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Table 1.  Summary of the Studies on Immunogenetics of Graves’ Ophthalmopathy 
Polymorphism Population  Sample  Size  Study 
Cytokines 
IL-3, rs40401   Chinese 
GO (+) = 190 
GO (-) = 561 
Zhu et al. [65], 2010 
IL-4, rs2070874  Chinese 
GO (+) = 190 
GO (-) = 561 
Zhu et al. [65], 2010 
IL-5, rs2069812  Chinese 
GO (+) = 190 
GO (-) = 561 
Zhu et al. [65], 2010 
IL-1 , rs3917368 Taiwan  Chinese 
GO (+) = 200 
GO (-) = 271 
Liu et al. [81], 2010 
IL-1 , rs1143643 Taiwan  Chinese 
GO (+) = 200 
GO (-) = 271 
Liu et al. [81], 2010 
IL-1 , rs1800587   Han Chinese 
GO (+) = 190 
GO (-) = 570 
Liu et al. [66], 2010 
IL-1 , rs16944 Han  Chinese 
GO (+) = 190 
GO (-) = 570 
Liu et al. [66], 2010 
IL-4, -1098 T/G  Iranian 
GO (+) = 50 
GO (-) = 57 
Khalilzadeh et al. [62], 2010 
IL-4, -33 C/T  Iranian 
GO (+) = 50 
GO (-) = 57 
Khalilzadeh et al. [62], 2010 
TGF- , +869 T/C  Iranian 
GO (+) = 50 
GO (-) = 57 
Khalilzadeh et al. [62], 2010 
TGF- , +915 G/C  Iranian 
GO (+) = 50 
GO (-) = 57 
Khalilzadeh et al. [62], 2010 
IL-10, -819 C/T  Iranian 
GO (+) = 50 
GO (-) = 57 
Khalilzadeh et al. [62], 2010 
IL-1 , -889 C/T  Iranian 
GO (+) = 50 
GO (-) = 57 
Khalilzadeh et al. [61], 2009 
IL-1 receptor antagonist 
Mspa-1 11100 T/C 
Iranian 
GO (+) = 50 
GO (-) = 57 
Khalilzadeh et al. [61], 2009 
IL-12, -1188 A/C  Iranian 
GO (+) = 50 
GO (-) = 57 
Anvari et al. [63], 2009 
TNF- , -238, G/A  Iranian 
GO (+) = 50 
GO (-) = 57 
Anvari et al. [63], 2009 
IFN- 
UTR 5644, A/T 
Iranian 
GO (+) = 50 
GO (-) = 57 
Anvari et al. [63], 2009 
IL-8, rs2227306  Chinese 
GO (+) = 164 
GO (-) = 478 
Gu et al. [126], 2009 
IL-23R, rs2201841  North American Caucasian 
GO (+) = 103 
GO (-) = 111 
Huber et al. [127], 2008 
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(Table 1). Contd….. 
Polymorphism Population  Sample  Size  Study 
IL-23R, rs10889677  North American Caucasian 
GO (+) = 103 
GO (-) = 111 
Huber et al. [127], 2008 
IL-16 
(rs4778889-rs1131445-rs4778641) 
Chinese 
GO (+) = 136 
GO (-) = 122 
Gu et al. [128], 2008 
TNF- , -863C/A  Chinese 
GO (+) = 54 
GO (-) = 60 
Yan et al. [69], 2005 
TNF- , -238G/A  Polish 
GO (+) = 106 
GO (-) = 122 
Bednarczuk et al. [70], 2004 
TNF- , -1031 T/C  Japanese 
GO (+) = 62 
GO (-) = 111 
Kamizono et al. [68], 2000 
TNF- , -863C/A  Japanese 
GO (+) = 62 
GO (-) = 111 
Kamizono et al. [68], 2000 
CTLA-4 
CTLA-4, +49 GA  Iranian 
GO (+) = 105 
GO (-) = 100 
Esteghamati et al. [85], 2009 
CTLA-4, -318 CT  Chinese 
GO (+) = 33 
GO (-) = 56 
Zhang et al. [129], 2006 
CTLA-4, -318 CT  Chinese 
GO (+) = 142 
GO (-) = 121 
Han et al. [130], 2006 
CTLA-4, +49 GA  Polish 
GO (+) = 50 
GO (-) = 49 
Frydecka et al. [86], 2004 
CTLA-4, +49 GA  British 
GO (+) = 94 
GO (-) = 94 
Vaidya et al. [87], 2003 
CTLA-4, +1822 CT  British 
GO (+) = 94 
GO (-) = 94 
Vaidya et al. [87], 2003 
CTLA-4, +49 GA  British 
GO (+) = 129 
GO (-) = 172 
Vaidya et al. [88], 1999 
HLA
HLA-DRB1*120101 Korean 
GO (+) = 17 
GO (-) = 113 
Jang et al. [107], 2010 
HLA-DRB1*03 (DR3)  Italian 
GO (+) = 54 
GO (-) = 38 
Buzzetti et al. [92], 1999 
HLA-DRB1*07 (DR7)  German 
GO (+) = 96 
GO (-) = 78 
Badenhoop et al. [104], 1992 
HLA-DRB3*01 (DR52)  German 
GO (+) = 214 
GO (-) = 90 
Boehm et al. [110], 1992 
HLA-DPB1*0201 (DPB2·1)  British 
GO (+) = 43 
GO (-) = 48 
Weetman et al. [99], 1990 
HLA-DRB1*04 (DR4)  Canadian 
GO (+) = 64 
GO (-) = 69 
Frecker et al. [105], 1988 
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Polymorphism Population  Sample  Size  Study 
HLA-DRB1*03 (DR3)  Hungarian 
GO (+) = 62 
GO (-) = 55 
Frecker et al. [102], 1986 
HLA-B*08 Hungarian 
GO (+) = 62 
GO (-) = 55 
Frecker et al. [102], 1986 
HLA-B*08 Hungarian 
GO (+) = 84 
GO (-) = 79 
Stenszky et al. [101], 1983 
HLA-DRB1*03 (DR3)  German 
GO (+) = 101 
GO (-) = 49 
Schleusener et al. [131], 1983 
Other Markers 
CD103 , rs11652878  Chinese 
GO (+) = 203 
GO (-) = 281 
Liu et al. [119], 2010 
CD86, rs9831894  Taiwan Chinese 
GO (+) = 200 
GO (-) = 271 
Liao et al. [118], 2010 
Toll-like receptor-9, rs287084   Taiwan Chinese 
GO (+) = 200 
GO (-) = 271 
Liao et al. [117], 2010 
Toll-like receptor-9, 
rs352140  
Taiwan Chinese 
GO (+) = 200 
GO (-) = 271 
Liao et al. [117], 2010 
Glucocorticoid receptor 
BcII allele  
Hungarian 
Severe GO = 70 
Mild GO = 25 
Boyle et al. [116], 2008 
Protein tyrosine phosphatases, Non-
Receptor Type 12 
rs1468682, rs4729535 rs17467232  
British 
mild/moderate GO = 354 
GO (-) = 366
Syed et al. [114], 2007 
NF B, -94ins/del ATTG  Japanese 
GO (+) = 123 
GO (-) = 301 
Kurylowicz et al. [115], 2007 
ICAM-1, 1405A/G  Polish  
GO (+) = 108 
GO (-) = 127 
Kretowski, et al. [113], 2003 
cytokine that has also been the target of a new therapy for 
GO [67]. A group of authors from Japan showed a positive 
association between two polymorphisms in the 5-
promoter/enhancer region (-1031T/C and -863C/A) of the 
TNF gene and the development and severity of GO [68]. 
Their results at position -863C/A were replicated by a study 
from China [69]. However, another study in Polish-
Caucasian patients did not show a significant association at 
this position [70]. In the latter study, a significant association 
was found only for the polymorphism at position -238G/A 
[70].  
  In a study from Japan, eight different alleles named as 
IFN- *1 to IFN- *8 were identified, among which IFN- *3 
and IFN- *5 were associated with GO [71]. A study from 
Iran showed a significant association between GO and a 
polymorphism at IFN-   UTR 5644A/T [63].  
  The major members of the IL-1 superfamily are IL-1 ,
IL-1, and the IL-1 receptor antagonist (IL-1RA). IL-1  and 
- are pro-inflammatory cytokines and the IL-1RA competes 
for receptor binding with IL-1  and IL-1 [72]. There are 
significant differences in the expression and control of the 
IL-1RA gene between orbital fibroblasts derived from 
patients with active GO and healthy individuals [73]. 
Cultured retro-orbital fibroblasts derived from patients with 
GO express and release significantly lower quantities of 
intracellular and soluble IL-1RA compared with normal 
fibroblasts [74-75]. It is suggested that an imbalance 
between IL-1 and IL-1RA may play an important role in the 
pathogenesis of GO [73]. Although IL1-RA gene 
polymorphisms have not been linked with GO in all studies 
[76-78], a significant association was found in a study from 
Iran [61]. IL-1 stimulates retro-orbital fibroblast 
proliferation, glycosaminoglycan synthesis, and expression 
of immunomodulatory molecules by retro-orbital fibroblasts 
[42, 79]. IL-1 can induce the expression of adhesion 
molecules, cytokines, complement regulatory proteins, and 
stress proteins in thyroid cells and retro-orbital fibroblasts 
[80]. Polymorphisms in IL-1-  and IL-1- genes have shown 
conflicting associations, i.e. both negative [59, 77] and 
positive [61, 66, 81], with GO. A recent meta-analysis 
covering data from Taiwan, Iran, and Poland showed that the 570 Current Genomics, 2011, Vol. 12, No. 8 Khalilzadeh et al.
rs1800587 (IL1- , -889 T/C) and rs16944 (IL-1 , -511 A/G) 
polymorphisms may confer susceptibility to GO in the Asian 
population [66].  
  A summary of other cytokines with significant 
associations with GO is provided in Table 1.
4.2. CTLA-4 
  The CTLA-4 gene encodes for a negative regulator of the 
T-cell immune response and seems to be an immunogenetic 
associate of several autoimmune diseases [82-84]. The A/G 
polymorphism at position 49 in exon 1 has been the focus of 
many studies [85-87]. This polymorphism results in an 
amino acid exchange (Threonine/Alanine) which may lead to 
decreased expression of CTLA-4. In a study from the UK, 
the 49A/G polymorphism was associated with an increased 
risk of GO [88]. This result was later confirmed by another 
study from the same research group [87] and a recent study 
by our group from Iran [85]. Also, the CTLA-4 A49G 
polymorphism might predict remission rates in patients 
treated with antithyroid drugs [89]. The relationship between 
the CTLA-4 gene polymorphisms and the development of 
GO has been the subject of several studies in different 
populations. Some [85-88], but not all [90-96], of these 
studies are in support of a significant association. 
Unfortunately, most of these studies are under-powered and 
have used different definitions for GO or enrolled patients 
with different degrees of GO severity. A meta-analysis by 
Bednarczuk  et al. [97] argued against a significant 
association between the CTLA-4 A49G polymorphism and 
GO. The authors emphasized that their meta-analysis had 
considerable limitations due to discrepancies in design and 
data presentation of the individual reports. 
Fig. (1). A schematic diagram summarizing the immunogenetic pathophysiology of Graves’ ophthalmopathy. 
Disease manifestations are the product of a close interaction between orbital fibroblasts and T-cell lymphocytes. Various classes of 
immunomodulators (e.g. HLA antigens, CTLA-4, and cytokines) mediate this interaction. Polymorphisms in immunomodulator genes can
alter the interaction between T-cells and orbital fibroblasts and impact disease susceptibility and progression.  Immunogenetics of Graves' Ophthalmopathy  Current Genomics, 2011, Vol. 12, No. 8    571
4.3. HLA 
  HLA gene polymrphisms are one of the susceptibility 
factors proposed for GO. There are two types of HLA 
molecules: class I (A, B and C) and class II (DP, DQ and 
DR). HLA molecules are encoded by a cluster of genes 
forming a complex on chromosome 6 (MHC) [98]. HLA 
class II plays an important role in the activation of CD4+ T 
lymphocytes which have a key role in the regulation of 
autoimmune reactions leading to GD and GO. Therefore, 
HLA class II genes are one of the key candidates for the 
development of GD and GO [99]. 
  A major limitation in studying autoimmune associations 
of different HLA alleles is the strong linkage disequilibrium 
between HLA alleles and alleles of undefined neighboring 
loci which may exert the primary effect [70, 100]. Therefore, 
functional studies of the biological effects of different HLA 
alleles are needed to determine the true effects of these 
potential genetic associates of GO. For example, the HLA 
class I antigen, HLA-B8, was described to be associated with 
GO [101]. However, further investigation revealed that this 
effect was most probably due to a linkage disequilibrium 
between HLA-B8 and HLA-class II molecules, especially 
HLA-DR3 (HLA-DRB1*03 alleles) [102-103]. There are 
several pieces of evidence in support of the role of HLA-
DRB1 in GO [92, 102, 104-107]. Contradictory results, 
however, exist as well [70, 90, 92, 95]. HLA-DRB1 
polymorphism at position 74 is of pathophysiological 
relevance, because it has a central role in autoantigen 
presentation by HLA-DR to T cells [108]. HLA-DR7 alleles 
are also reported to have a role in genetic susceptibility to 
GO [104, 109]. Based on isolated studies, an association 
between HLA-DR4, HLA-DPB 2·1/8 and HLA-DRB3 
alleles and GO seems likely [99, 105, 110]. A meta-analysis 
in 2007 did not show any significant association between 
GO and polymorphisms in HLA-DR3, -DR4 and -DR7 [97]. 
Studies from Japan suggest that HLA-A11, -B5, -DW12 and 
-DR14 are associated with GO, whereas HLA-DPw2 confers 
a protective effect [111-112].  
4.4. Other Genetic Factors 
  GO was recently reported to be associated with 
polymorphisms in the gene for intracellular adhesion 
molecule-1 (ICAM-1), which plays a major role in leukocyte 
circulation and migration [113], as well as polymorphisms in 
genes for lymphoid protein tyrosine phosphatase (PTPN22: a 
negative regulator of T-cell activation) [114], nuclear factor-
kappa-B (NFB; a transcription factor activated by various 
intra- and extra-cellular stimuli such as cytokines) [115], 
glucocorticoid receptors [116], TLR-9 (TLR: a family of 
pattern-recognition receptors involved in eliciting 
innate/adaptive immune responses and chronic 
inflammation) [117], CD86 (B7 molecules; factors that 
provide a costimulatory signal for T cell activation and 
survival and are ligands for CD28 and CTLA-4 on T cell 
surface) [118], and CD103 (Integrin-alpha E) [119]. Other 
reports suggest that functional polymorphisms in the 
PTPN22, CD40, NFB inhibitor, MAP3K7IPT and Fc 
receptor-like 3 molecule (FCRL-3) genes are not associated 
with GO [120-122]. Theoretically, the TSHR gene is a 
suitable candidate for genetic susceptibility to GD because it 
is a thyroid-specific gene, and it is well known that 
antibodies against the TSHR play a major role in activation 
of thyroid cells and hyperthyroidism [123]. However, case-
control studies have not been successful in finding an 
association between polymorphisms in the TSHR gene and 
GO [124-125]. The debate is ongoing.  
5. CONCLUSIONS 
  We provide an exhaustive review of the available studies 
on the immunogentics of GO. Several important patterns 
arise from this review. First, more than half of the studies are 
from Asian populations. Considering that ethnicity may play 
an important role in the immunogenetics of autoimmune 
conditions, the results from one ethnicity cannot be extended 
to the other ethnicities in a straightforward manner. There is 
a scarcity of data from Caucasian populations and a 
complete lack of data from Africa. Studies from these 
ethnicities would be illuminating. Second, the three most 
frequently reported associations with GO are for CTLA-4, 
HLA-DRB-1, and TNF- . The interplay between these three 
factors might be a significant determinant of GO 
susceptibility and pathogenesis. However, particular caution 
should be practiced when considering HLA genes. These 
genes, as described above, tend to be in linkage 
disequilibrium with neighboring genes, which might also be 
important players in GO pathogenesis. Finally, association 
studies like those reviewed here only serve as a start point 
for further studies. No causal relationships can be extracted 
from a mere association. One of the best ways to enrich the 
results of the observed associations is by functional studies 
that investigate the relationship between a given 
polymorphism and serum level of the resulting protein. For 
GO, however, one also needs to know the relationship 
between the polymorphisms of interest and local (i.e. orbital) 
concentrations of the resulting protein. Very little attention 
has been paid to this point, a fact which has limited our 
understanding of the disease pathogenesis.  
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